Summary

￭  IPG0916 is a potent, selective preclinical antibody antagonist targeting CCR6, a key chemokine receptor that drives Th17-mediated autoimmune diseases including psoriasis.

￭  Unlike conventional broad-acting immunosuppressants, IPG0916 acts through a highly selective mechanism of action that blocks the migration of pathogenic Th17 cells to inflamed tissues.

￭   As a targeted biologic with strong combination therapy potential and a robust preclinical profile, IPG0916 is well-positioned to enter the large, fast-growing global autoimmune therapy market, addressing the unmet need for safer, more effective treatment options.

Mechanism of Action

Th17 cells are a critical T cell subset that secrete pro-inflammatory cytokines (e.g., IL-17, IL-22), which are core mediators of tissue damage across a broad range of autoimmune diseases. The CCR6 receptor is predominantly expressed on Th17 cells and functions as a cellular homing signal, directing these cells to sites of inflammation via binding to its endogenous ligand CCL20.

IPG0916 is a monoclonal antibody that specifically binds to CCR6 and blocks its interaction with CCL20. This action effectively inhibits the migration and tissue accumulation of pathogenic Th17 cells. By reducing local pathogenic cell burden, IPG0916 is designed to downregulate inflammatory cytokine secretion and attenuate the core inflammatory cascade driving disease progression. Preclinical data confirm that IPG0916 potently blocks CCR6-mediated intracellular signaling with nanomolar IC₅₀ potency.

Key Differentiation

￭   High Target Specificity: IPG0916 selectively targets CCR6-expressing Th17 cells, which is expected to minimize the risk of systemic immunosuppression and associated adverse effects—a key limitation of conventional broad-acting therapies.

￭   Strong Combination Therapy Potential: Its targeted mechanism of action makes it an ideal candidate for combination regimens with other biologics, including anti-TNF-α and anti-IL-17 antibodies, to deliver deeper, more durable therapeutic responses.

￭   Robust Preclinical Profile: IPG0916 is a potent human CCR6 antagonist that binds with high affinity to both human and cynomolgus monkey CCR6. It has also demonstrated excellent stability under stress conditions, supporting a robust developability profile.

￭   Competitive Development Position: IPG0916 ranks among the top 3 CCR6-targeted candidates globally in clinical development progress, placing it in a strong competitive position as it advances toward clinical-stage development.

Current Development & Status

IPG0916 is currently in the preclinical development stage. IND-enabling studies are actively ongoing to support subsequent clinical trial initiation.